NeuroSearch's license partner Abbott initiates clinical Phase I study with ABT-107

Announcement                                                                    


NeuroSearch's license partner Abbott initiates clinical Phase I study with      
ABT-107                                                                         

NeuroSearch's development and license partner Abbott has enrolled and dosed the 
first patients in a clinical Phase I study with the drug candidate ABT-107,     
which has treatment potential within a variety of CNS disorders.                

ABT-107 is a neuronal nicotinic receptor (NNR) modulator, which has shown       
promise in preclinical models relevant for the treatment of cognitive deficits. 

According to the terms of the license agreement, Abbott has all rights to       
ABT-107 and will finance all costs relating to the development and              
commercialisation of the drug. NeuroSearch will receive milestone payments as   
well as royalties on Abbott's global sales, if the drug is successfully         
commercialised.                                                                 

The initiation of the Phase I study with ABT-107 releases a milestone payment to
NeuroSearch.                                                                    

NeuroSearch maintain financial expectations for 2007 of a loss before           
recognition of associates and other equity interests in the region of DKK 80 -  
100 million.                                                                    


Asger Aamund                                                                    
Chairman of the Board                                                           


Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone +45 4460 8212 or 
+45 40175103                                                      

NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen
Stock Exchange (NEUR). Our core business covers the development of novel drugs, 
based on a broad and well-established drug discovery platform focusing on ion   
channel and CNS disorders. A substantial part of the company's activities are   
partner financed through a broad alliance with GlaxoSmithKline (GSK) and        
collaborations with among others Abbott and Astellas. The drug pipeline         
comprises nine clinical development programmes: ACR16 for the treatment of      
Huntington's disease (under preparation for Phase III), tesofensine for the     
treatment of obesity/type 2 diabetes (Phase II), NS2359 for the treatment of    
depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 for   
the treatment of epilepsy and pain (Phase II), ABT-894 for the treatment of ADHD
(Phase II) and neuropathic pain (Phase I) in partnership with Abbott, ACR16 for 
the treatment of schizophrenia (Phase I) in partnership with Astellas and ACR325
for the treatment of psychoses such as bipolar disorder (Phase I). In addition, 
NeuroSearch has a broad portfolio of preclinical drug candidates and has equity 
interests in several biotech companies.